Quantcast
Last updated on April 16, 2014 at 14:39 EDT

Latest Amylin Stories

2013-12-19 08:28:04

SAN DIEGO, Dec. 19, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for treatment of diabetes, announced today that Mark G. Foletta has been appointed to its Board of Directors. (Logo: http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a) Mr. Foletta is a seasoned financial executive with over 30 years of corporate experience. He was most recently senior vice president and Chief Financial Officer at Amylin...

2013-11-12 12:08:40

People get type 2 diabetes. So do cats. But rats don't, and neither do dogs. Subtle differences in the shape of proteins protect some and endanger others. "All mammals make this same protein called amylin, and it only differs a little bit from species to species," says Martin Zanni, a University of Wisconsin–Madison chemistry professor. "The mammals that get type 2 diabetes, their amylin proteins aggregate in the pancreas into plaque that kills the cells around them. As a result, you...

2013-09-17 08:31:30

Industry-leading team assembled to accelerate clinical development of the biotechnology company's dendritic cell therapy for Type 1 diabetes EDGEWATER, N.J., Sept. 17, 2013 /PRNewswire/ -- DiaVacs, Inc., a clinical stage biotechnology company focused on the goal of curing autoimmune diseases, with its first indication being Type 1 diabetes mellitus (T1DM), today announced that it has appointed Orville Kolterman, MD, as Chief Medical Officer. In this role, Dr. Kolterman will assume...

2012-12-24 20:20:12

OSAKA, Japan and DEERFIELD, Ill., Dec. 24, 2012 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, Inc., originally signed in October 2009, to co-develop and commercialize compounds for obesity. The companies announced in August 2011 their decision to discontinue the development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity....

2012-08-09 02:29:39

BOONTON, N.J., Aug. 9, 2012 /PRNewswire/ --Unigene Laboratories, Inc. (OTCBB: UGNE) today announced financial results for the second quarter ended June 30, 2012 and provided a corporate review on key development programs and strategic initiatives. SECOND QUARTER 2012 FINANCIAL SUMMARY Unigene announced that its net loss for the three months ended June 30, 2012 decreased to $5.5 million or $(0.06) per share from $8.4 million or $(0.09) per share for the corresponding period in 2011....

2012-07-12 06:24:31

CHICAGO, July 12, 2012 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include WellPoint Inc. (NYSE:WLP), AMERIGROUP Corporation (NYSE:AGP), Bristol-Myers Squibb Company (NYSE:BMY), Amylin Pharmaceuticals, Inc. (Nasdaq:AMLN), and Eli Lilly & Company (NYSE:LLY). (Logo:...

2012-07-09 06:29:03

DALLAS, July 9, 2012 /PRNewswire/ -- Securities lawyers at Goldfarb LLP are investigating alleged violations of shareholder protection laws by officers and directors of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) in connection with a buyout for $31.00 per share to Bristol-Myers Squibb. Concerned AMLN investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbllp.com about their rights and remedies. "Amylin's recently approved diabetes drug, Bydureon,...

2012-07-03 10:22:58

BALA CYNWYD, Pa., July 3, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (Nasdaq - AMLN) relating to the proposed acquisition by Bristol-Myers Squibb Company ("Bristol-Myers"). Under the terms of the transaction, Amylin shareholders will receive only $31.00 in cash for each of Amylin stock they own. The investigation concerns possible...

2012-07-02 06:24:56

NEW YORK, July 2, 2012 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NASDAQ: AMLN) breached its fiduciary duty to its shareholders in agreeing to sell Amylin to Bristol-Myers Squibb Company (NYSE: BMY). (Logo: http://photos.prnewswire.com/prnh/20120202/MM47134LOGO ) Under the terms of the agreement, Amylin shareholders will receive $31.00 in cash for each share they own. The investigation...

2012-07-02 02:23:47

NEW YORK, July 2, 2012 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Amylin Pharmaceuticals, Inc. ("Amylin" or the "Company") (NsadaqGS: AMLN) related to the proposed acquisition of the Company by Bristol-Myers Squibb Company. The transaction is valued at approximately $5.3 billion or $31 per share. This investigation concerns whether the Board of Directors of Amylin breached their fiduciary...